|
| |
|
THE FOLLOWING PUBLICATIONS BY
DR. KENNETH OFFIT
and his research
colleagues (2002-2006) ARE A CONTINUING RECORD OF
INNOVATIVE CLINICAL AND LABORATORY GENETIC RESEARCH SUPPORTED IN PART BY
LYMPHOMA FOUNDATION GRANTS
|
|
CANCER AND LYMPHOMA GENETICS
2006
Localization of Breast Cancer Susceptibility Loci by Genome-Wide SNP
Linkage Disequilibrium Mapping
Ellis NA, KirchhoffT, MitraN, Ye T, Chuai S, Huang H, Nafa K, Norton L,
Neuhausen S, Gordon D, Streuwing JP, Naiod S Offit K.. Genetic
Epidemiology 2006,30(1):48-61
MDM2 SNP309 accelerates tumor
formation in a gender-specific and hormone-dependent manner Bond GL,
Hirshfield KM, KirchhoffT, Alexe G, Bond EE, Robins H, Basrtel F,
Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ.. Cancer
Research 2006,66(10):5104-10
Accuracy of BRCAI and BRCA2 founder mutation analysis in formalin-fixed
and paraffin-embedded (FFPE) tissue
Adank MA, Brogi E, Bogomolniy F, Wadsworth EA, Lafaro KJ, Yee CJ,
KirchhoffT, Meijers-Heijboer EJ, KauffNK, Boyd J, Offit K.. Familial
Cancer 2006 (in press)
Cancer Genetic Testing and Assisted Reproduction.
Offit K, Kohut K, Clagett B, Wadsworth E, Cummings S, White M, Sagi M,
Bernstein D, Davis JG. Journal of Clinical Oncology 2006.
Electronically published online by the Journal of Clinical Oncology
in July, 2006 and was formally published in October 2006
2004-2005
The Genetics
of Familial Lymphomas,
R. Siddiqui, K. Onel, F. Facio, K. Offit, Current Oncology
Reports 2004, 6:380-387
The TP53 Mutational spectrum and frequency of CHEK2* 1100delC in Li
Fraumeni-like kindreds Siddiqui, R, Onel K, Facio F, Nafa D, Robles-Diaz R, Kauff N, Huang
H, Robson M, Ellis N, Offit K Familial Cancer
2005; 4(2):177-81
Combined genetic
assessment of transforming growth factor-beta signaling pathway variants
may predict breast cancer risk. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty
C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen
Y, Ahsan H, Offit K, Pasche B. Cancer Research 2005;
65(8):3454-61.
Estrogen receptor
genotypes and haplotypes associated with breast cancer risk.
Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang
H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG,
Parl FF, Broder S, Dean M, Offit K. Cancer Research
2004; 64:8891-900.
Localization of cancer susceptibility genes by genome-wide
single-nucleotide polymorphism linkage-disequilibrium mapping.
Mitra N, Ye
TZ, Smith A, Chuai S, Kirchhoff T, Peterlongo P, Nafa K, Phillips MS,
Offit K, Ellis NA.
Cancer Research
2004; 64: 8116-25.
|
|
Hereditary ovarian cancer in Ashkenazi Jews.
Robles-Diaz L,
Goldfrank D, Kauff N, Robson M, Offit K Familial Cancer
2004; 3:259-64
A636P testing in Ashkenazi Jews. Guillem JG, Moore HG, Palmer, C, Glogowski E,
Finch R, Nafa K, Markowitz AJ,
Offit K, Ellis NA. Familial Cancer 2004; 3:223-227
Pleomorphic
expression of a germline kit mutation in a large kindred with
gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Robson ME, Glogowski E, Sommer G, Antonescu CR, Khedoudja N, Maki
RG, Ellis N, Besmer P, Brennan M, Offit K. Clinical Cancer
Research
2004;10:1250-4.
Functional and
genomic approaches reveal an ancient CHEK2 allele associated with breast
cancer in the Ashkenazi Jewish population.
Shaag A, Walsh T,
Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee
MK, Ellis N, Offit K, Levy-Lahad E, King MC. Human Molecular Genetics
2005; 14:555-63
|
|
2002-2003
TGFBR1*6A and Cancer Risk: A
Meta-Analysis of Seven Case-Control Studies,
V.G. Kaklamani, N. Hou,
Y. Bian, J. Reich, K. Offit, L.S. Michel, W.S. Rubinstein, A.
Rademaker, B. Pasche, Journal of Clinical Oncology, Vol 21,
No 17 (September 1), 2003: pp3236-3243
Rare Variants of ATM and Risk for Hodgkin’s Disease and
Radiation-associated Breast Cancers,
K.
Offit,, S.
Gilad, S. Paglin, P. Kolachana, L.C. Roisman, K. Nafa, V. Yeugelewitz, M.
Gonzales, M. Robson, D. McDermott, H.H. Pierce, N.D. Kauff, P. Einat, S.
Jhanwar, J.M. Satagopan, C. Oddoux, N. Ellis, R. Skaliter, J. Yahalom,
Clinical Cancer Research, Vol. 8, 3813-3819, December 2002.
Analysis of Mismatch Repair Defects in the Familial Occurrence of Lymphoma
and Colorectal Cancer,
Teruya-Feldstein,
J., Greene, J., Cohen, L., Popplewell, L., Ellis, N.A., Offit,
K., Leukemia and Lymphoma, 2002 Vol. 43 (8), pp. 1619-1626.
Similar Patterns of Genomic Alterations Characterize Primary Mediastinal
Large-B-Cell Lymphoma and Diffuse Large-B-Cell Lymphoma,
Palanisamy,
N., Abou-Elella, A., Chaganti, S.R., Houldsworth, J. Offit, K.,
Louie, D.C., Terayu-Feldstein, J., Cigudosa, J.C., Rao, P.H., Sanger, W.G.,
Weisenburger, D.D., Chaganti, R.S.K., Genes, Chromosomes & Cancer,
33:114-122 (2002).
Differential recruitment of caspase 8 to cFlip confers sensitivity or
resistance to Fas-mediated apoptosis in a subset of familial lymphoma
patients,
C. Bäumler,
F. Duan, K. Onel, B. Rapaport, S. Jhanwas, K. Offit, K.B. Elkon,
Leukemia Research 27 (2003) 841-851 |
|
BREAST AND OVARIAN CANCER GENETICS
2002-2005
Combined genetic
assessment of transforming growth factor-beta signaling pathway variants
may predict breast cancer risk. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty
C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen
Y, Ahsan H, Offit K, Pasche B. Cancer Research 2005;
65(8):3454-61.
Estrogen receptor
genotypes and haplotypes associated with breast cancer risk.
Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang
H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG,
Parl FF, Broder S, Dean M, Offit K. Cancer Research
2004; 64:8891-900.
Hereditary ovarian cancer in Ashkenazi Jews.
Robles-Diaz L,
Goldfrank D, Kauff N, Robson M, Offit K Familial Cancer
2004; 3:259-64
Functional
and genomic approaches reveal an ancient CHEK2 allele associated with
breast cancer in the Ashkenazi Jewish population.
Shaag A, Walsh T,
Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee
MK, Ellis N, Offit K, Levy-Lahad E, King MC. Human Molecular Genetics
2005; 14:555-63
Shared
Genetic Susceptibility to Breast Cancer, Brain Tumors, and Fanconi Anemia,
K. Offit,
O. Levran, B. Mullaney, K. Mah, K. Nafa, S.D. Batish, R. Diotti, H.
Schneider, A. Deffenbaugh, T. Scholl, V.K. Proud, M. Robson, L. Norton, N.
Ellis, H. Hanenberg, A.D. Auerbach, Journal of the National Cancer
Institute, Vol. 95, No. 20, October 15, 2003
Localization of Breast Cancer
Susceptibility Loci by Genome-Wide SNP Linkage Disequilibrium Mapping,
N.A. Ellis, T. Kirchhoff, N. Mitra,
T.-Z. Ye, S. Chuai, H. Huang, K. Nafa, L. Norton, S. Neuhausen, J.P.
Struewing, S. Narod, K. Offit, (in preparation).
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer
in BRCA Mutation Carriers,
Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J.,
Ellis, N., Hensley, M., Boyd, J., Borgen, P., Norton, L., Offit, K.,
J Clin Oncol, Vol 20, No 5 (March 1), 2002: pp 1260-1268.
Risk-Reducing Salpingo-Oophorectomy in Women with a BRCA1 or BRCA2
Mutation,
Kauff, N.D., Satagopan, J.M., Robson, M.E., Scheuer, L., Hensley, M.,
Hudis, C.A., Ellis, N.A., Boyd, J., Borgen, P.I., Barakat, R.R., Norton,
L., Offit, K., N Engl J Med, Vol. 346 , No. 21 May 23, 2002:
pp 1609-1615.
Frequency of CHEK2*1100delC in New York breast cancer cases and
controls,
K.
Offit, H. Pierce,
T. Kirchhoff, P. Kolachana, B. Rapaport, P. Gregersen, S. Johnson, O.
Yossepowitch, H. Huang, J. Satagopan, M. Robson, L. Scheuer, BMC
Medical Genetics, 2003,
4,
http://www.biomedcentral.com/1471-2350/4/1.
BRCA1
AND BRCA2 Germline Mutations in Lymphoma Patients,
O. Yossepowitch, N. Olvera, J. M. Satagopan, H. Huang, S. Jhanwar, B.
Rapaport, J. J. Boyd, K. Offit, Leukemia and Lymphoma, 2003
Vol. 44 (1), pp. 127-131
COLON
CANCER and OTHER GASTROINTESTINAL GENETICS
2004
Pleomorphic Characteristics of a Germ-Line KIT Mutatioin in a Large
Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and
Dysphagia
M.E. Robson, E. Glogowski, G. Sommer,
C.R. Antonescu, K. Nafa, R.G. Maki, N. Ellis, P. Besmer, M. Brennan, K.
Offit, Clinical Cancer Research, Vol. 10, 1250-1254, February
15, 2004
2002-2003
BLM
Heterozygosity and the Risk of Colorectal Cancer,
Gruber, S.B., Ellis, N.A., Rennert, G., Offit, K., et al.
Science, Vol 297, 20 September 2002
The Founder Mutation MSH2*1906G®C
Is an Important Cause of Herditary Nonpolyposis Colorectal Cancer in the
Ashkenazi Jewish Population,
W.D.
Foulkes, I. Thiffault, S.B. Gruber, M. Horwitz, N. Hamel, C. Lee, J. Shia,
A. Markowitz, A. Figer, E. Friedman, D. Farber, C.M.T. Greenwood, J.D.
Bonner, K. Nafa, T. Walsh, V. Marcus, L. Tomsho, J. Gebert, F.A. Macrae,
C.L. Gaff, B. Bressac-de Paillerets, P.K. Gregersen, J.N. Weitzel, P.H.
Gordon, E. MacNamara, M.-C. King, H. Hampel, A. de la Chapelle, J Boyd,
K. Offit, G. Rennert, G. Chong, and N.A. Ellis. Am. J. Hum. Genet.
71:1395-1412, 2002.
A636P Is Associated with Early-Onset Colon Cancer in Ashkenazi Jews,
J.G.
Guillem, B.S. Rapaport, T. Kirchhoff, P. Kolachana, K. Nafa, E. Glogowski,
R. Finch, H. Huang, W.D. Foulkes, A. Markowitz, N.A. Ellis, K. Offit,
J Am Coll Surg., Vol. 196, No. 2, 222-225, February 2003.
PEDIATRIC CANCER GENETICS
2004-2005
The TP53 Mutational
spectrum and frequency of CHEK2* 1100delC in Li Fraumeni-like kindreds
Siddiqui, R, Onel K, Facio F, Nafa D, Robles-Diaz R, Kauff N,
Huang H, Robson M, Ellis N, Offit K Familial Cancer
2005; 4(2):177-81
The
FANCD1/BRCA2*6174DELT Mutation is Rare in Sporadic Pediatric
Medulloblastoma,
K. Onel, T. Kirchhoff, J.C. Allen, E. Jiminez,
K. Offit, (in preparation)
**Dr. Kenneth Offit
is
the Director of the Clinical Genetics
Service at the Memorial Sloan Kettering Cancer Center and author of
Clinical Cancer Genetics
|
|
YOUR
CONTRIBUTIONS PLAY AN IMPORTANT PART IN MOVING BASIC RESEARCH FROM THE
LABORATORY TO THE BEDSIDE
|
|
FOR ADDITIONAL INFORMATION...
CONTACT
THE LYMPHOMA FOUNDATION
or you can
return to review other CLINICIAN SCIENTISTS
SUPPORTED BY LYMPHOMA FOUNDATION GRANTS or
return to the
PUBLICATION PAGE
GO TOP
|
|
▲HOME
▲SCIENTISTS
▲RESEARCH
▲
EVENTS
▲
BOARD
▲
FELLOWS
▲BREAST
CANCER ▼PUBLICATIONS
▼CONTACT
US

The Lymphoma Foundation is a nationwide not for
profit foundation dedicated to funding clinical and basic laboratory cancer
research and applying the knowledge developed by the clinician scientists to the general welfare
and education of all cancer patients.
© Copyright 2006 THE LYMPHOMA
FOUNDATION All rights reserved |
|